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Abstract
Objective We conducted a systematic review and meta-analysis to assess the available literature regarding the surgical and 
oncologic outcomes of patients undergoing salvage radical cystectomy (SV-RC) for recurrence or failure of bladder sparing 
therapy (BST) for muscle-invasive bladder cancer (MIBC).
Methods We searched MEDLINE (PubMed), EMBASE and Google Scholar databases in May 2020. We included all studies 
of patients with ≥ cT2N0/xM0 bladder cancer that were eligible for all treatment modalities at the time of treatment decision 
who underwent BST including radiotherapy (RTX). A meta-analysis was conducted to calculate the pooled rate of several 
variables associated with an increased need for SV-RC. Study quality and risk of bias were assessed using MINORS criteria.
Results 73 studies comprising 9110 patients were eligible for the meta-analysis. Weighted mean follow-up time was 
61.1 months (range 12–144). The pooled rate of non-response to BST and local recurrence after BST, the two primary 
reasons for SV-RC, was 15.5% and 28.7%, respectively. The pooled rate of SV-RC was 19.2% for studies with a follow-up 
longer than 5 years. Only three studies provided a thorough report of complication rates after SV-RC. The overall complica-
tion rate ranged between 67 and 72% with a 30-day mortality rate of 0–8.8%. The pooled rates of 5 and 10-year disease-free 
survival after SV-RC were 54.3% and 45.6%, respectively.
Conclusion Approximately one-fifth of patients treated with BST with a curative intent eventually require SV-RC. This pro-
cedure carries a proportionally high rate of complications and is usually accompanied by an incontinent urinary diversion.
Keywords MIBC · Bladder sparing treatment · Bladder · Cancer · Salvage cystectomy · Radiotherapy
Introduction
Data from large meta-analyses suggest that bladder sparing 
therapy (BST) could offer equal oncologic outcomes com-
pared to radical cystectomy (RC) in well-selected patients 
with muscle-invasive bladder cancer (MIBC) [1–3]. The 
most effective BST strategy consists of maximal transure-
thral resection of bladder tumor (TURBT) followed by 
radiochemotherapy (RCT) [4]. This treatment strategy was 
primarily used for the elderly, frail patients who were ineligi-
ble for RC [5–7]. Nowadays, multiple guidelines support the 
use of BST in the form of a trimodal therapy (TMT) as an 
alternative to primary RC with curative intent for selected, 
well-informed and compliant patients, who desire to retain 
their bladder [4, 8–10]. Despite the failure of all randomized 
controlled trials due to accrual (e.g. NCT 02716896 and 
SPARE [11]), the oncological efficacy of TMT seems non-
inferior to primary RC in well-selected patients [1–6].
Patients usually would prefer a BST, as it is considered 
tolerable due to its minimal invasiveness with genuinely 
manageable toxicity [12, 13]. However, a significant propor-
tion of patients may eventually need a salvage radical cys-
tectomy (SV-RC) due to non-response to BST or local recur-
rence [14–16]. For an alternative therapy to be embraced, 
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it needs to also ensure that in addition to a low failure rate, 
the unfortunate cases can be salvaged with minimal adverse 
events. However, irradiated tissues are usually more fragile 
and difficult to dissect, leading to an increased risk of com-
plications following SV-RC [17–21]. In addition, the quality 
of life after SV-RC may not be similar to primary RC, as the 
optimal patient for TMT has a unifocal cT2 tumor that is 
fully resectable without carcinoma in situ or hydronephrosis 
[4]. Patients fulfilling these criteria could also be candidates 
for a high class, nerve-sparing primary RC with continent 
urinary diversion.
We, therefore, conducted a systematic review to evalu-
ate the surgical and oncologic outcomes following SV-RC 
after BST with a curative intent. We also performed a meta-
analysis to investigate the pooled incidence rate of SV-RC 
and assessed the variables associated with an increased like-
lihood of requirement for SV-RC.
Methods
Search strategy for identification of studies
This meta-analysis was carried out based on the guide-
lines of the Preferred Reporting Items for Meta-Analyses 
of Observational Studies in Epidemiology Statement and 
registered on PROSPERO (ID: CRD42020187685) [22]. 
In May 2020, a literature search on MEDLINE (PubMed), 
EMBASE and Google Scholar databases was performed 
using a Boolean operator and the keywords: salvage cystec-
tomy, rescue surgery, radiotherapy, trimodal therapy, blad-
der sparing therapy, multimodal therapy, bladder preserva-
tion, radiotherapy, radiochemotherapy, pelvic radiation and 
muscle invasive bladder cancer. Additionally, reference lists 
of the retrieved articles were analyzed to identify further 
studies. Studies lacking original patient data, abstracts, and 
non-English articles were excluded. The primary outcome of 
interest was the pooled rate of SV-RC, as well as the surgical 
and oncologic outcomes of patients treated with SV-RC for 
BST failure. Secondary outcomes of interest were variables 
associated with a previously reported increased likelihood 
for SV-RC [23].
Inclusion criteria
We included all studies of patients with ≥ cT2N0/xM0 blad-
der cancer who underwent BST which included radiotherapy 
(RTX). Patients had to be eligible for all treatment modali-
ties at the time of first-line treatment decision. The choice 
of treatment modality was usually based on patients and/or 
physicians’ preferences as well as participation in clinical 
trials. Studies that focused explicitly on elderly patients or 
patients unfit for surgery (at time of BST) were excluded, 
as there are limited treatment options for these patients and 
SV-RC will frequently not be feasible despite being other-
wise required. To focus on modern surgical and radiation 
treatment, we only included studies published between Janu-
ary 2000 and May 2020. To analyze a homogeneous cohort, 
we excluded studies that focused on primary partial cystec-
tomy or lymph node dissection (LND), brachytherapy or 
only TURBT/chemotherapy as part of BST. Studies report-
ing the outcome of SV-RC following pelvic radiotherapy 
for non-bladder cancer malignancies were excluded. Patient 
cohorts that focused on pure variants of urothelial carcinoma 
were also excluded, as there is little data on the value of BST 
in these patients. Studies reporting results of mixed cohorts 
were included. Repeated publications from the same authors 
or institutions were excluded, except for publications with 
updated or new data from the same institution.
Data extraction
Data were extracted independently by two authors. Titles 
and abstracts were screened to determine whether they met 
inclusion criteria. Full-text publications of all studies not 
primarily excluded were obtained and reviewed to check 
eligibility. If rates were not reported, they were calculated 
using the number of included patients as denominator, when-
ever it was possible. Non-response to BST was defined as a 
stable or progressive disease within 6 months after the initial 
treatment. Perioperative complications were defined as any 
complications within 30 days of SV-RC. Early SV-RC was 
defined as a SV-RC within 6 months of BST. Local recur-
rence was defined as intravesical recurrence. Missing data 
were obtained by contacting the authors of the relevant stud-
ies, if needed. All discrepancies regarding data extraction 
were resolved by consensus with co-investigators.
Quality assessment
As the vast majority of included studies were non-rand-
omized interventional studies, assessment of study quality 
and risk of bias was performed using the methodological 
index for non-randomized studies (MINORS) criteria [24]. 
MINORS is a validated tool, which consist of eight different 
items for the quality assessment of non-comparative studies. 
A high risk of bias was attributed for studies with less than 
12 points.
Statistical analysis
If sufficient data were available for evaluation, a meta-anal-
ysis of proportions was conducted to calculate the weighted 
summary overall proportion. These pooled rates represent 
the average from multiple studies weighted by the inverse of 
their sampling variances and are presented along with 95% 
1759World Journal of Urology (2021) 39:1757–1768 
1 3
confidence intervals (95% CI) calculated using a normal 
approximation [25]. The proportion of interest was re-cal-
culated from the relevant numerator (event) and denominator 
(total cases), if possible. Depending on the distribution of 
proportions, either no or logistic transformation was applied 
[25]. When significant heterogeneity (p value of < 0.05 in 
the Cochrane Q test and I2 > 50%) was observed, a random-
effects model (DerSimonian and Laird) was applied. The 
predominantly small sample sizes and retrospective study 
design prevented multivariable meta-regression due to ina-
bility to properly adjust for the effects of confounders. As it 
has been shown to be problematic in meta-analyses of pro-
portions, assessment of publication bias using funnel plots 
was not performed [26]. All analyses were conducted using 
R Studio, Version 3.6.3.
Results
Overall, we identified 73 studies comprising 9110 patients 
who underwent primary BST with curative intent accord-
ing to our inclusion criteria (Fig. 1). The characteristics of 
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Fig. 1  Flow diagram of the study selection procedure for the systematic review and meta-analysis
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included patients and the applied study methodology are 
shown in Supplementary Table 1 [58–118]. Weighted mean 
follow-up time was 61.1 months (range 12–144 months).
Pooled rate of salvage radical cystectomy
The pooled rate of all subsequently necessary SV-RC was 
15.5% (95% CI 13.0–18.0, I2 = 91%, Fig. 2). If only stud-
ies with a follow-up longer than 5 years were included, 
this rate rose to 19.2% (95% CI 15.4–23.0, I2 = 92%). 
The proportion of early and late SV-RC was equally 
balanced (55.7% vs. 44.3%). Pooled rate of incontinent 
urinary diversion was 91.1% for all reported cases (95% 
CI 76.1–97.0, I2 = 68%, logistic transformation applied). 
In the series of Chahal et al. which compared the out-
come of SV-RC and primary RC, 8.3% in the primary RC 
group had a continent urinary diversion vs. only 3.5% in 
the SV-RC group. The pooled rate of 5- and 10-year DFS 
after SV-RC was 54.3% (95% CI 48.6–60.1, I2 = 79%) and 
45.6% (95% CI 41.6–49.6, I2 = 0%, fixed effect model), 
respectively.
Fig. 2  Forest plots showing the pooled rates of salvage cystectomy (left) and local recurrence (right) for studies following bladder sparing treat-
ment of muscle-invasive bladder cancer
1761World Journal of Urology (2021) 39:1757–1768 
1 3
Complications rates of SV‑RC
Only three studies provided a thorough report of complica-
tions after SV-RC, while two further studies provided partial 
reports. Of these, four studies reported the overall complica-
tion rate, which ranged between 67 and 72.2% [27–30]. Two 
study groups found that the overall complication rates were 
not significantly worse for SV-RC and primary RC (Chahal 
et al. [29]: 75% vs 71.4%, Iwai et al. [28]: 67% vs. 57%). The 
rate of major complications was found to be higher following 
SV-RC compared to primary RC (22% vs. 12%) [28]. Cha-
hal et al. reported that the perioperative complications rate 
was lower for primary RC in comparison to SV-RC (37% vs 
47.1%) [29]. With respect to specific complications, Iwai 
et al. report a higher rate of overall urinary anastomosis-
related complications (11% vs. 2%, p = 0.007) and major 
gastrointestinal complications (14% vs. 4%, p = 0.02) in 
SV-RC vs. primary RC patients [28]. Similar, Chahal et al. 
reported a higher rate of bowel leakage following SV-RC, 
in comparison to patients treated with primary RC (8.7% 
vs 3%) [29].
30-day mortality rates for SV-RC-treated patients were 
generally low (Supplementary Table 2), but were higher 
than those for primary RC (30 day mortality 8.8% vs 3.1%; 
3-month mortality: 19.2% vs 14.5%) [29]. Compared to pri-
mary RC, SV-RC, therefore, seems to be associated with 
an increased risk of both complications and perioperative 
mortality.
Variables associated with an increased rate of SV‑RC
No study focused on analyzing variables that could predict 
the need for SV-RC. Less than 2% of the patients underwent 
SV-RC due to non-oncologic reasons [14, 15, 31, 32]. Local 
recurrence and non-response to BST were found to be the 
primary reasons for SV-RC. Pooled rate of local recurrence 
was 27.9% (95% CI 23.9–31.9, I2 = 92%), this increased to 
32.9% for studies with longer than 5 years follow-up (95% 
CI 27.0–38.7, I2 = 91%, Fig. 2). In our study, pooled rate of 
complete response to BST was 75.1% (95% CI 70.8–79.4, 
I2 = 95%), while pooled rate for non-response (stable or pro-
gressive disease) was 15.5% (95% CI 11.9–19.0, I2 = 93%). 
Several studies reported that a significant proportion of 
patients were not salvageable after BST treatment failure 
(12–52%) [14, 33, 34].
Two large series noted that in patients with an incom-
plete primary TURBT before BST, the rate of SV-RC was 
higher compared to the rest of the cohort (e.g. 42% vs. 
22%) [32, 35]. In our study, weighted pooled rate of incom-
plete TURBT before BST was 38.6% (95% CI 27.9–49.3, 
I2 = 99%). Patients undergoing SV-RC had a higher propor-
tion of cT3 and cT4 diseases compared to those who did not 
need a SV-RC (43% vs. 30%, p = 0.007) [35].
Quality assessment
In terms of methodologic quality, MINORS scores ranged 
from 7 to 16 (mean 12.7, median 12). Overall, 80.8% (59/73) 
of all studies included into the meta-analysis were, therefore, 
found to be without a risk of bias.
Discussion
The prerequisite criteria for BST to be considered as an ade-
quate alternative to primary RC in patients with MIBC need 
to be addressed. It is obvious that the equivalence of BST 
to primary RC, the standard of care in this disease space, 
can only be assessed in a prospective randomized controlled 
clinical trial. Since such a study is nearly impossible, due 
to the patients and physicians’ lack of enthusiasm, we have 
attempted to investigate the criteria that would allow BST 
to be accepted as an alternative to primary RC (i.e. low fail-
ure rates and a salvage strategy after treatment failure that 
offers an acceptable morbidity and mortality). We found that 
one in five patients treated with primary BST with a cura-
tive intent subsequently required SV-RC. However, these 
patients may have represented only a proportion of failures, 
as not all patients will be eligible for SV-RC. Failure of BST 
and subsequent time delay might deprive patients of other 
treatments alternatives [14, 33, 34]. Nevertheless, reported 
bladder preservation rates of 70–85% seem to be encour-
aging, especially as further developments in BST, like a 
tretramodale approach or immunotherapy, might improve 
treatment outcomes and subsequently reduce the likelihood 
of subsequent SV-RC [36].
Despite the significant rate of failure in BST leading 
to subsequent SV-RC, only 3 out of 73 studies thoroughly 
reported the outcomes of SV-RC. Even with advances in 
intra- and perioperative care, SV-RC remains a challenging 
surgery. Indeed, it leads to overall complication rates rang-
ing between 67 and 72% [27–30]. If standardized definitions 
are applied and a meticulous workup of all complications is 
performed, these rates are very likely to increase even more 
[37]. While a non-randomized comparison is not without 
bias, modern primary RC shows much lower complication 
rates [38, 39]. Mortality rates of SV-RC were found to be 
low in our systematic review, but still data suggest worse 
early and 3 months survival rates following SV-RC in com-
parison to primary RC [29, 40, 41]. Patients undergoing 
SV-RC lose their opportunity for a high-quality primary 
RC (i.e. nerve sparing with a continent urinary diversion). 
While it still remains unclear if one form urinary diversion 
is superior to another in terms of quality of life, it is believed 
that most patients will favor a continent urinary diversion 
[42]. SV-RC, however, usually entails an incontinent uri-
nary diversion due to irradiation damage to the pelvic tissue. 
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Even though we did not find any data on the use of nerve-
sparing SV-RC, it seems unlikely that this is possible, let 
alone be successful. While a successful BST seems to have 
little effect on quality of life, a non-nerve sparing approach 
and an incontinent urinary diversion following SV-RC may 
potentially decrease the quality of life after failure of BST 
[43]. This needs to be addressed in the counselling of MIBC 
patients regarding the risks, benefits and alternatives to pri-
mary RC. Patients also need to be counselled on the high 
local recurrence rate following BST, which necessitates a 
lifelong follow-up and further invasive procedures, thus 
increasing morbidity and health care costs [44–46].
Predictors of SV-RC need to be investigated to improve 
patient selection. In agreement with the literature on onco-
logic outcome after BST, our findings suggest that patients 
with multifocal tumors, hydronephrosis non-organ confined 
disease, incomplete TURBT or carcinoma in situ should not 
be selected for BST [12]. Despite intensified research, there 
is a persistent lack of clinical useful biomarkers for patient 
selection, as all reported results are still exploratory [47–53]. 
So far, as seen in patients undergoing primary RC, there 
remains a substantial risk for understaging even in patients 
seemingly ideal for BST [54–56]. As LND remains the most 
accurate method for complete pathological staging and thus 
for detection of more aggressive tumors while simultane-
ously treating micrometastases, neoadjuvant chemotherapy 
followed by RC and LND is likely to remain the gold stand-
ard for treatment of MIBC in cisplatin and surgically fit 
patients, as it allows the best risk stratification [57].
The main limitation of this study is its retrospective 
design. Due to the differences in staging techniques, tumor 
subtypes, inclusion criteria and treatment modalities the 
final cohort analyzed was found to be very heterogene-
ous. Also, we identified only three studies that thoroughly 
reported the outcomes after SV-RC, as most studies only 
briefly mentioned the rates of necessary SV-RC. Despite an 
acceptable quality of the studies included, prospective tri-
als assessing precisely the risk of SV-RC and the oncologic 
outcomes are highly needed.
Conclusion
Approximately one-fifth to one-third of patients treated with 
BST with a curative intent eventually a SV-RC. This proce-
dure has a proportionally high rate of complications and, 
while primarily entailing a non-tissue sparing (i.e. nerve-
sparing) approach, usually is accompanied by an incontinent 
urinary diversion. The resulting decreased quality of life 
needs to be taken into consideration during the counselling 
of MIBC patients regarding the risks, benefits and alterna-
tives (i.e. BST) to primary RC.
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